| langue originale | Anglais |
|---|---|
| Pages (de - à) | 1951-1962 |
| Nombre de pages | 12 |
| journal | Journal of Clinical Oncology |
| Volume | 38 |
| Numéro de publication | 17 |
| Les DOIs | |
| état | Publié - 24 avr. 2020 |
Accès au document
Autres fichiers et liens
Contient cette citation
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Dans: Journal of Clinical Oncology, Vol 38, Numéro 17, 24.04.2020, p. 1951-1962.
Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs
TY - JOUR
T1 - HER2-Low breast cancer
T2 - Pathological and clinical landscape
AU - Tarantino, Paolo
AU - Hamilton, Erika
AU - Tolaney, Sara M.
AU - Cortes, Javier
AU - Morganti, Stefania
AU - Ferraro, Emanuela
AU - Marra, Antonio
AU - Viale, Giulia
AU - Trapani, Dario
AU - Cardoso, Fatima
AU - Penault-Llorca, Frédérique
AU - Viale, Giuseppe
AU - Andrè, Fabrice
AU - Curigliano, Giuseppe
N1 - Funding Information: AstraZeneca (Inst), Hutchison MediPharma (Inst), OncoMed (Inst), MedImmune (Inst), Stem CentRx (Inst), Roche (Inst), Curis (Inst), Verastem (Inst), Zymeworks (Inst), Syndax (Inst), Lycera (Inst), Rgenix (Inst), Novartis (Inst), Mersana (Inst), Millennium (Inst), TapImmune (Inst), Eli Lilly (Inst), BerGenBio (Inst), Medivation (Inst), Pfizer (Inst), Tesaro (Inst), Boehringer Ingelheim (Inst), Eisai (Inst), H3 Biomedicine (Inst), Radius Health (Inst), Acerta Pharma (Inst), Takeda (Inst), Macrogenics (Inst), AbbVie (Inst), Immunomedics (Inst), Fujifilm (Inst), eFFECTOR Therapeutics (Inst), Merus (Inst), Nucana (Inst), Regeneron (Inst), Leap Therapeutics (Inst), Taiho Pharmaceutical (Inst), EMD Serono (Inst), Daiichi Sankyo (Inst), ArQule (Inst), Syros Pharmaceuticals (Inst), Clovis Oncology (Inst), CytomX Therapeutics (Inst), InventisBio (Inst), Deciphera (Inst), Unum Therapeutics (Inst), Sermonix Pharmaceuticals (Inst), Sutro (Inst), Aravive (Inst), Zenith Epigenetics (Inst), Arvinas (Inst), Torque (Inst), Harpoon (Inst), Fochon (Inst), Black Diamond (Inst), Orinove (Inst), Molecular Templates (Inst), Silverback Therapeutics (Inst), Seattle Genetics (Inst), Puma Biotechnology (Inst), Compugen (Inst), G1 Therapeutics (Inst), Karyopharm Therapeutics (Inst), Torque (Inst) Roche (Inst), Merck (Inst), Exelixis (Inst), Pfizer (Inst), Eli Lilly (Inst), Novartis (Inst), Bristol-Myers Squibb (Inst), Eisai (Inst), AstraZeneca (Inst), NanoString Technologies (Inst), Cyclacel (Inst), Nektar (Inst), Immunomedics (Inst), Odonate Therapeutics (Inst) ARIAD (Inst), AstraZeneca (Inst), Baxalta/Servier Affaires (Inst), Bayer (Inst), Eisai Farmaceutica (Inst), Guardant Health (Inst), Merck Sharp & Dohme (Inst), Pfizer (Inst), Puma CO (Inst), Queen Mary University of London (Inst), Roche (Inst), Piqur (Inst) Roche (Inst), AstraZeneca (Inst), Nanostring (Inst) AstraZeneca (Inst), Novartis (Inst), Pfizer (Inst), Eli Lilly (Inst), Roche (Inst), Daiichi (Inst)
PY - 2020/4/24
Y1 - 2020/4/24
UR - http://www.scopus.com/inward/record.url?scp=85086050965&partnerID=8YFLogxK
U2 - 10.1200/JCO.19.02488
DO - 10.1200/JCO.19.02488
M3 - Review article
C2 - 32330069
AN - SCOPUS:85086050965
SN - 0732-183X
VL - 38
SP - 1951
EP - 1962
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 17
ER -